Premium
CCN6 enhances ICAM‐1 expression and cell motility in human chondrosarcoma cells
Author(s) -
Fong YiChin,
Lin ChihYang,
Su YiChang,
Chen WenChi,
Tsai FuuJen,
Tsai ChangHai,
Huang ChihYang,
Tang ChihHsin
Publication year - 2012
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.22720
Subject(s) - cyr61 , cancer research , focal adhesion , ctgf , mapk/erk pathway , signal transduction , microbiology and biotechnology , chemistry , biology , receptor , growth factor , biochemistry
Chondrosarcoma is a type of highly malignant tumor with a potent capacity to invade locally and cause distant metastasis. Chondrosarcoma shows a predilection for metastasis to the lungs. CCN6 is a cysteine‐rich protein that belongs to the CCN (Cyr61, CTGF, and Nov) family of matricellular proteins. However, the effects of CCN6 on human chondrosarcoma cells are largely unknown. In this study, we found that CCN6 increased the migration and the expression of intercellular adhesion molecule‐1 (ICAM‐1) in human chondrosarcoma cells. αvβ3 and αvβ5 integrin monoclonal antibody and mitogen‐activated protein kinase (MEK) inhibitors (PD98059 and U0126) inhibited the CCN6‐induced increase of the migration and ICAM‐1 up‐regulation of chondrosarcoma cells. CCN6 stimulation increased the phosphorylation of focal adhesion kinase (FAK), MEK, and extracellular signal‐regulated kinase (ERK). In addition, activator protein‐1 (AP‐1) inhibitors suppressed the cell migration and ICAM‐1 expression enhanced by CCN6. Moreover, CCN6 increased AP‐1 luciferase activity and binding of c‐Jun to the AP‐1 element on the ICAM‐1 promoter. Taken together, our results indicate that CCN6 enhances the migration of chondrosarcoma cells by increasing ICAM‐1 expression through the αvβ3 and αvβ5 integrin receptor, FAK, MEK, ERK, c‐Jun, and AP‐1 signal transduction pathway. J. Cell. Physiol. 227: 223–232, 2012. © 2011 Wiley Periodicals, Inc.